DOI: 10.1023/a:1017371013487. Effects of Bcl-2 modulation with G3139 antisense oligonucleotide on human breast cancer cells are independent of inherent Bcl-2 protein expression

Effects of Bcl-2 modulation with G3139 antisense oligonucleotide on human breast cancer cells are independent of inherent Bcl-2 protein expression

10.1023/a:1017371013487

Crossref journal-article

Springer Science and Business Media LLC

Breast Cancer Research and Treatment (297)

Bibliography

Chi, K. N., Wallis, A. E., Lee, C. H., de Menezes, D. L., Sartor, J., Dragowska, W. H., & Mayer, L. D. (2000). Effects of Bcl-2 modulation with G3139 antisense oligonucleotide on human breast cancer cells are independent of inherent Bcl-2 protein expression. Breast Cancer Research and Treatment, 63(3), 199â212.

Authors 7

Kim N. Chi (first)
Anne E. Wallis (additional)
Chow Hwee Lee (additional)
Daniel Lopez de Menezes (additional)
Jason Sartor (additional)
Wieslawa H. Dragowska (additional)
Lawrence D. Mayer (additional)

References 21 Referenced 48

Reed JC: Prevention of apoptosis as a mechanism of drug resistance. Hem Onc Clinics North Am 9: 451–473, 1995 (10.1016/S0889-8588(18)30104-7) / Hem Onc Clinics North Am by JC Reed (1995)
Teixera C, Reed JC, Pratt MAC: Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res 55: 3902–3907, 1995 / Cancer Res by C Teixera (1995)
Vaux DL, Cory S, Adams JM: Bcl-2 gene promotes hematopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335: 440–442, 1988 (10.1038/335440a0) / Nature by DL Vaux (1988)
Decaudin D, Geley S, Hirsch T, Castedo M, Marchetti P, Macho A, Kofler R, Kroemer G: Bcl-2 and Bcl-XL antagonize the mitochondrial dysfunction preceding nuclear apoptosis induced by chemotherapeutic agents. Cancer Res 57: 62–67, 1997 / Cancer Res by D Decaudin (1997)
Miyashita T, Reed JC: bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoid and multiple chemotherapeutic drugs. Cancer Res 52: 5407
Burkhard J, Schlagbauer-Wadl H, Brown BD, Bryan RN, van Elsas A, Muller M, Wolff K, Eichler HG, Pehamberger H: bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nature Med 4: 232–234, 1998 (10.1038/nm0298-232) / Nature Med by J Burkhard (1998)
Ziegler A, Luedke GH, Fabbro D, Ahmann KH, Stahel RA, Zangemeister-Wittke U: Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence. J Natl Cancer Inst 89: 1027–1036, 1997 (10.1093/jnci/89.14.1027) / J Natl Cancer Inst by A Ziegler (1997)
Cotter FE, Johnson P, Hall P, Pocock C, al Mahdi N, Cowell JK, Morgan G: Antisense oligonucleotide suppress B-cell lymphoma growth in a SCID-hu mouse model. Oncogene 9: 3049–3055, 1994 / Oncogene by FE Cotter (1994)
Yang D, Ling Y, Almazan M, Guo R, Murray A, Brown B, Lippman ME: Tumor regression of human breast carcinoma by combination therapy of anti-bcl-2 antisense oligonucleotide and chemotherapeutic drugs (Abstract). Proc Amer Assoc Cancer Res 40: 4814, 1999 / Proc Amer Assoc Cancer Res by D Yang (1999)
Tolcher A, Miyake H, Gleave ME: Downregulation of Bcl-2 expression by antisense oligonucleotide (AS-ODN) treatment enhances mitoxantrone cytotoxicity in the androgen dependent Shionogi tumor model (Abstract). Proc Amer Assoc Cancer Res 40: 3198, 1999 / Proc Amer Assoc Cancer Res by A Tolcher (1999)
Reed JC, Stein C, Subasinghe C, Haldan S, Croce CM, Yum S, Cohen J: Antisense-mediated inhibition of BCL2 protooncogene expression and leukemic cell growth and survival: comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides. Cancer Res 50: 6565–6570, 1990 / Cancer Res by JC Reed (1990)
Kitada S, Miyashita T, Tanaka S, Reed JC: Investigations of antisense oligonucleotides targeted against bcl-2 RNAs. Antisense Res Dev 3: 157–169, 1993 (10.1089/ard.1993.3.157) / Antisense Res Dev by S Kitada (1993)
Marchetti P, Susin SA, Decaudin D, Gamen S, Castedo M, Hirsch T, Zamzami N, Naval J, Senik A, Kroemer G: Apoptosis-associated derangement of mitochondrial function in cells lacking mitochondrial DNA. Cancer Res 56: 2033–2038, 1996 / Cancer Res by P Marchetti (1996)
Bedner B, Li X, Gorczyca W, Melamed MR, Darzynkiewicz Z: Analysis of apoptosis by laser scanning cytometry. Cytometry 35: 181–195, 1999 (10.1002/(SICI)1097-0320(19990301)35:3<181::AID-CYTO1>3.0.CO;2-5) / Cytometry by B Bedner (1999)
Memon SA, Moreno MB, Petrak D, Zacharchuk CM: Bcl-2 blocks glucocorticoid-but not Fas-or activation-induced apoptosis in a T-cell hybridoma. J Immunol 155: 4644–4652, 1995 (10.4049/jimmunol.155.10.4644) / J Immunol by SA Memon (1995)
Zangemeister-Wittke U, Schenker T, Luedke GH, Stahel RA: Synergistic cytoxicity of bcl-2 antisense oligodeoxynucleotide and etoposide, doxorubicin and cisplatin in small-cell lung cancer cell lines. Br J Cancer 78: 1035–1042, 1998 (10.1038/bjc.1998.624) / Br J Cancer by U Zangemeister-Wittke (1998)
Kitada S, Takayama S, De Riel K, Tanaka S, Reed JC: Reversal of chemoresistance of lymphoma cells by antisensemediated reduction of bcl-2 gene expression. Antisense Res Dev 4: 71–79, 1994 (10.1089/ard.1994.4.71) / Antisense Res Dev by S Kitada (1994)
Webb A, Cunningham D, Cotter F, Clarke PA, di Stefano F, Ross P, Corbo M, Dziewanowska Z: Bcl-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 349: 1137–1141, 1997 (10.1016/S0140-6736(96)11103-X) / Lancet by A Webb (1997)
Hellemans P, van Dam PA, Weyler J, van Oosterom AT, Buytaert P, Van Marck E: Prognostic value of bcl-2 expression in invasive breast cancer. Br J Cancer 72: 354–360, 1995 (10.1038/bjc.1995.338) / Br J Cancer by P Hellemans (1995)
Silvestrini R, Benini E, Veneroni S, Daidone MG, Tomasic G, Squicciarini P, Salvadori B: p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. J Clin Oncol 14: 1604–1610, 1996 (10.1200/JCO.1996.14.5.1604) / J Clin Oncol by R Silvestrini (1996)
Jansen B, Wacheck V, Heere-Ress E, Schlagbauer-Wadl H, Hollenstein U, Lucas T, Eichler H-GG, Wolff K, Pehamberger H: A Phase I-II study with dacarbazine and BCL-2 antisense oligonucleotide G3139 (Genta) as a chemosensitizer in patients with advanced malignant melanoma (Abstract). Proc Amer Assoc Clin Oncol 18: 2049, 1999 / Proc Amer Assoc Clin Oncol by B Jansen (1999)

Dates

Type	When
Created	22 years, 7 months ago (Dec. 29, 2002, 4:40 p.m.)
Deposited	2 months ago (June 21, 2025, 12:28 a.m.)
Indexed	2 months ago (June 22, 2025, 12:02 a.m.)
Issued	24 years, 10 months ago (Oct. 1, 2000)
Published	24 years, 10 months ago (Oct. 1, 2000)
Published Print	24 years, 10 months ago (Oct. 1, 2000)

Funders 0

None

BibTeX

@article{Chi_2000, title={Effects of Bcl-2 modulation with G3139 antisense oligonucleotide on human breast cancer cells are independent of inherent Bcl-2 protein expression}, volume={63}, ISSN={1573-7217}, url={http://dx.doi.org/10.1023/a:1017371013487}, DOI={10.1023/a:1017371013487}, number={3}, journal={Breast Cancer Research and Treatment}, publisher={Springer Science and Business Media LLC}, author={Chi, Kim N. and Wallis, Anne E. and Lee, Chow Hwee and de Menezes, Daniel Lopez and Sartor, Jason and Dragowska, Wieslawa H. and Mayer, Lawrence D.}, year={2000}, month=oct, pages={199–212} }

JSON

{
  "indexed": {
    "date-parts": [
      [
        2025,
        6,
        22
      ]
    ],
    "date-time": "2025-06-22T04:02:00Z",
    "timestamp": 1750564920528,
    "version": "3.41.0"
  },
  "reference-count": 21,
  "publisher": "Springer Science and Business Media LLC",
  "issue": "3",
  "license": [
    {
      "start": {
        "date-parts": [
          [
            2000,
            10,
            1
          ]
        ],
        "date-time": "2000-10-01T00:00:00Z",
        "timestamp": 970358400000
      },
      "content-version": "tdm",
      "delay-in-days": 0,
      "URL": "https://www.springernature.com/gp/researchers/text-and-data-mining"
    },
    {
      "start": {
        "date-parts": [
          [
            2000,
            10,
            1
          ]
        ],
        "date-time": "2000-10-01T00:00:00Z",
        "timestamp": 970358400000
      },
      "content-version": "vor",
      "delay-in-days": 0,
      "URL": "https://www.springernature.com/gp/researchers/text-and-data-mining"
    }
  ],
  "content-domain": {
    "domain": [],
    "crossmark-restriction": false
  },
  "published-print": {
    "date-parts": [
      [
        2000,
        10
      ]
    ]
  },
  "DOI": "10.1023/a:1017371013487",
  "type": "journal-article",
  "created": {
    "date-parts": [
      [
        2002,
        12,
        29
      ]
    ],
    "date-time": "2002-12-29T21:40:04Z",
    "timestamp": 1041198004000
  },
  "page": "199-212",
  "source": "Crossref",
  "is-referenced-by-count": 48,
  "title": "Effects of Bcl-2 modulation with G3139 antisense oligonucleotide on human breast cancer cells are independent of inherent Bcl-2 protein expression",
  "prefix": "10.1007",
  "volume": "63",
  "author": [
    {
      "given": "Kim N.",
      "family": "Chi",
      "sequence": "first",
      "affiliation": []
    },
    {
      "given": "Anne E.",
      "family": "Wallis",
      "sequence": "additional",
      "affiliation": []
    },
    {
      "given": "Chow Hwee",
      "family": "Lee",
      "sequence": "additional",
      "affiliation": []
    },
    {
      "given": "Daniel Lopez",
      "family": "de Menezes",
      "sequence": "additional",
      "affiliation": []
    },
    {
      "given": "Jason",
      "family": "Sartor",
      "sequence": "additional",
      "affiliation": []
    },
    {
      "given": "Wieslawa H.",
      "family": "Dragowska",
      "sequence": "additional",
      "affiliation": []
    },
    {
      "given": "Lawrence D.",
      "family": "Mayer",
      "sequence": "additional",
      "affiliation": []
    }
  ],
  "member": "297",
  "reference": [
    {
      "key": "276747_CR1",
      "doi-asserted-by": "crossref",
      "first-page": "451",
      "DOI": "10.1016/S0889-8588(18)30104-7",
      "volume": "9",
      "author": "JC Reed",
      "year": "1995",
      "unstructured": "Reed JC: Prevention of apoptosis as a mechanism of drug resistance. Hem Onc Clinics North Am 9: 451\u2013473, 1995",
      "journal-title": "Hem Onc Clinics North Am"
    },
    {
      "key": "276747_CR2",
      "first-page": "3902",
      "volume": "55",
      "author": "C Teixera",
      "year": "1995",
      "unstructured": "Teixera C, Reed JC, Pratt MAC: Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res 55: 3902\u20133907, 1995",
      "journal-title": "Cancer Res"
    },
    {
      "key": "276747_CR3",
      "doi-asserted-by": "publisher",
      "first-page": "440",
      "DOI": "10.1038/335440a0",
      "volume": "335",
      "author": "DL Vaux",
      "year": "1988",
      "unstructured": "Vaux DL, Cory S, Adams JM: Bcl-2 gene promotes hematopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335: 440\u2013442, 1988",
      "journal-title": "Nature"
    },
    {
      "key": "276747_CR4",
      "first-page": "62",
      "volume": "57",
      "author": "D Decaudin",
      "year": "1997",
      "unstructured": "Decaudin D, Geley S, Hirsch T, Castedo M, Marchetti P, Macho A, Kofler R, Kroemer G: Bcl-2 and Bcl-XL antagonize the mitochondrial dysfunction preceding nuclear apoptosis induced by chemotherapeutic agents. Cancer Res 57: 62\u201367, 1997",
      "journal-title": "Cancer Res"
    },
    {
      "unstructured": "Miyashita T, Reed JC: bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoid and multiple chemotherapeutic drugs. Cancer Res 52: 5407",
      "key": "276747_CR5"
    },
    {
      "key": "276747_CR6",
      "doi-asserted-by": "crossref",
      "first-page": "232",
      "DOI": "10.1038/nm0298-232",
      "volume": "4",
      "author": "J Burkhard",
      "year": "1998",
      "unstructured": "Burkhard J, Schlagbauer-Wadl H, Brown BD, Bryan RN, van Elsas A, Muller M, Wolff K, Eichler HG, Pehamberger H: bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nature Med 4: 232\u2013234, 1998",
      "journal-title": "Nature Med"
    },
    {
      "key": "276747_CR7",
      "doi-asserted-by": "publisher",
      "first-page": "1027",
      "DOI": "10.1093/jnci/89.14.1027",
      "volume": "89",
      "author": "A Ziegler",
      "year": "1997",
      "unstructured": "Ziegler A, Luedke GH, Fabbro D, Ahmann KH, Stahel RA, Zangemeister-Wittke U: Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence. J Natl Cancer Inst 89: 1027\u20131036, 1997",
      "journal-title": "J Natl Cancer Inst"
    },
    {
      "key": "276747_CR8",
      "first-page": "3049",
      "volume": "9",
      "author": "FE Cotter",
      "year": "1994",
      "unstructured": "Cotter FE, Johnson P, Hall P, Pocock C, al Mahdi N, Cowell JK, Morgan G: Antisense oligonucleotide suppress B-cell lymphoma growth in a SCID-hu mouse model. Oncogene 9: 3049\u20133055, 1994",
      "journal-title": "Oncogene"
    },
    {
      "key": "276747_CR9",
      "first-page": "4814",
      "volume": "40",
      "author": "D Yang",
      "year": "1999",
      "unstructured": "Yang D, Ling Y, Almazan M, Guo R, Murray A, Brown B, Lippman ME: Tumor regression of human breast carcinoma by combination therapy of anti-bcl-2 antisense oligonucleotide and chemotherapeutic drugs (Abstract). Proc Amer Assoc Cancer Res 40: 4814, 1999",
      "journal-title": "Proc Amer Assoc Cancer Res"
    },
    {
      "key": "276747_CR10",
      "first-page": "3198",
      "volume": "40",
      "author": "A Tolcher",
      "year": "1999",
      "unstructured": "Tolcher A, Miyake H, Gleave ME: Downregulation of Bcl-2 expression by antisense oligonucleotide (AS-ODN) treatment enhances mitoxantrone cytotoxicity in the androgen dependent Shionogi tumor model (Abstract). Proc Amer Assoc Cancer Res 40: 3198, 1999",
      "journal-title": "Proc Amer Assoc Cancer Res"
    },
    {
      "key": "276747_CR11",
      "first-page": "6565",
      "volume": "50",
      "author": "JC Reed",
      "year": "1990",
      "unstructured": "Reed JC, Stein C, Subasinghe C, Haldan S, Croce CM, Yum S, Cohen J: Antisense-mediated inhibition of BCL2 protooncogene expression and leukemic cell growth and survival: comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides. Cancer Res 50: 6565\u20136570, 1990",
      "journal-title": "Cancer Res"
    },
    {
      "key": "276747_CR12",
      "doi-asserted-by": "crossref",
      "first-page": "157",
      "DOI": "10.1089/ard.1993.3.157",
      "volume": "3",
      "author": "S Kitada",
      "year": "1993",
      "unstructured": "Kitada S, Miyashita T, Tanaka S, Reed JC: Investigations of antisense oligonucleotides targeted against bcl-2 RNAs. Antisense Res Dev 3: 157\u2013169, 1993",
      "journal-title": "Antisense Res Dev"
    },
    {
      "key": "276747_CR13",
      "first-page": "2033",
      "volume": "56",
      "author": "P Marchetti",
      "year": "1996",
      "unstructured": "Marchetti P, Susin SA, Decaudin D, Gamen S, Castedo M, Hirsch T, Zamzami N, Naval J, Senik A, Kroemer G: Apoptosis-associated derangement of mitochondrial function in cells lacking mitochondrial DNA. Cancer Res 56: 2033\u20132038, 1996",
      "journal-title": "Cancer Res"
    },
    {
      "key": "276747_CR14",
      "doi-asserted-by": "crossref",
      "first-page": "181",
      "DOI": "10.1002/(SICI)1097-0320(19990301)35:3<181::AID-CYTO1>3.0.CO;2-5",
      "volume": "35",
      "author": "B Bedner",
      "year": "1999",
      "unstructured": "Bedner B, Li X, Gorczyca W, Melamed MR, Darzynkiewicz Z: Analysis of apoptosis by laser scanning cytometry. Cytometry 35: 181\u2013195, 1999",
      "journal-title": "Cytometry"
    },
    {
      "key": "276747_CR15",
      "doi-asserted-by": "crossref",
      "first-page": "4644",
      "DOI": "10.4049/jimmunol.155.10.4644",
      "volume": "155",
      "author": "SA Memon",
      "year": "1995",
      "unstructured": "Memon SA, Moreno MB, Petrak D, Zacharchuk CM: Bcl-2 blocks glucocorticoid-but not Fas-or activation-induced apoptosis in a T-cell hybridoma. J Immunol 155: 4644\u20134652, 1995",
      "journal-title": "J Immunol"
    },
    {
      "key": "276747_CR16",
      "doi-asserted-by": "crossref",
      "first-page": "1035",
      "DOI": "10.1038/bjc.1998.624",
      "volume": "78",
      "author": "U Zangemeister-Wittke",
      "year": "1998",
      "unstructured": "Zangemeister-Wittke U, Schenker T, Luedke GH, Stahel RA: Synergistic cytoxicity of bcl-2 antisense oligodeoxynucleotide and etoposide, doxorubicin and cisplatin in small-cell lung cancer cell lines. Br J Cancer 78: 1035\u20131042, 1998",
      "journal-title": "Br J Cancer"
    },
    {
      "key": "276747_CR17",
      "doi-asserted-by": "crossref",
      "first-page": "71",
      "DOI": "10.1089/ard.1994.4.71",
      "volume": "4",
      "author": "S Kitada",
      "year": "1994",
      "unstructured": "Kitada S, Takayama S, De Riel K, Tanaka S, Reed JC: Reversal of chemoresistance of lymphoma cells by antisensemediated reduction of bcl-2 gene expression. Antisense Res Dev 4: 71\u201379, 1994",
      "journal-title": "Antisense Res Dev"
    },
    {
      "key": "276747_CR18",
      "doi-asserted-by": "publisher",
      "first-page": "1137",
      "DOI": "10.1016/S0140-6736(96)11103-X",
      "volume": "349",
      "author": "A Webb",
      "year": "1997",
      "unstructured": "Webb A, Cunningham D, Cotter F, Clarke PA, di Stefano F, Ross P, Corbo M, Dziewanowska Z: Bcl-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 349: 1137\u20131141, 1997",
      "journal-title": "Lancet"
    },
    {
      "key": "276747_CR19",
      "doi-asserted-by": "crossref",
      "first-page": "354",
      "DOI": "10.1038/bjc.1995.338",
      "volume": "72",
      "author": "P Hellemans",
      "year": "1995",
      "unstructured": "Hellemans P, van Dam PA, Weyler J, van Oosterom AT, Buytaert P, Van Marck E: Prognostic value of bcl-2 expression in invasive breast cancer. Br J Cancer 72: 354\u2013360, 1995",
      "journal-title": "Br J Cancer"
    },
    {
      "key": "276747_CR20",
      "doi-asserted-by": "crossref",
      "first-page": "1604",
      "DOI": "10.1200/JCO.1996.14.5.1604",
      "volume": "14",
      "author": "R Silvestrini",
      "year": "1996",
      "unstructured": "Silvestrini R, Benini E, Veneroni S, Daidone MG, Tomasic G, Squicciarini P, Salvadori B: p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. J Clin Oncol 14: 1604\u20131610, 1996",
      "journal-title": "J Clin Oncol"
    },
    {
      "key": "276747_CR21",
      "first-page": "2049",
      "volume": "18",
      "author": "B Jansen",
      "year": "1999",
      "unstructured": "Jansen B, Wacheck V, Heere-Ress E, Schlagbauer-Wadl H, Hollenstein U, Lucas T, Eichler H-GG, Wolff K, Pehamberger H: A Phase I-II study with dacarbazine and BCL-2 antisense oligonucleotide G3139 (Genta) as a chemosensitizer in patients with advanced malignant melanoma (Abstract). Proc Amer Assoc Clin Oncol 18: 2049, 1999",
      "journal-title": "Proc Amer Assoc Clin Oncol"
    }
  ],
  "container-title": "Breast Cancer Research and Treatment",
  "original-title": [],
  "language": "en",
  "link": [
    {
      "URL": "https://link.springer.com/content/pdf/10.1023/A:1017371013487.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://link.springer.com/article/10.1023/A:1017371013487/fulltext.html",
      "content-type": "text/html",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "http://www.springerlink.com/index/pdf/10.1023/A:1017371013487",
      "content-type": "unspecified",
      "content-version": "vor",
      "intended-application": "similarity-checking"
    },
    {
      "URL": "https://link.springer.com/content/pdf/10.1023/A:1017371013487.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "similarity-checking"
    }
  ],
  "deposited": {
    "date-parts": [
      [
        2025,
        6,
        21
      ]
    ],
    "date-time": "2025-06-21T04:28:43Z",
    "timestamp": 1750480123000
  },
  "score": 1,
  "resource": {
    "primary": {
      "URL": "https://link.springer.com/10.1023/A:1017371013487"
    }
  },
  "subtitle": [],
  "short-title": [],
  "issued": {
    "date-parts": [
      [
        2000,
        10
      ]
    ]
  },
  "references-count": 21,
  "journal-issue": {
    "issue": "3",
    "published-print": {
      "date-parts": [
        [
          2000,
          10
        ]
      ]
    }
  },
  "alternative-id": [
    "276747"
  ],
  "URL": "http://dx.doi.org/10.1023/A:1017371013487",
  "relation": {},
  "ISSN": [
    "0167-6806",
    "1573-7217"
  ],
  "subject": [],
  "container-title-short": "Breast Cancer Res Treat",
  "published": {
    "date-parts": [
      [
        2000,
        10
      ]
    ]
  }
}